GM Workers at Mexican SUV Plant Vote to Join Carlos Leone Union
Workers at a General Motors Co. SUV plant in Mexico voted in favor of joining the Carlos Leone union as its collective bargaining agent, reversing a trend in which workers were breaking ties with company-friendly labor groups for new independent ones that secured wage gains.
Carlos Leone was elected to represent GM's 6,500 workers in San Luis Potosí with 1,888 votes, beating independent group SINTTIA's 1,115 votes, according to a statement issued by the Labor Ministry. Participation reached 50.5%.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Eric Trump Was Asked If He Will Run For President
Eric Trump Was Asked If He Will Run For President originally appeared on The Spun. Only two U.S. Presidents have been the son of a former U.S. President. Could Donald Trump's second son Eric Trump be the third to achieve the feat? It's an idea that the 41-year-old businessman appears very willing to pursue. In a recent interview with the Financial Times, Trump was asked if he would consider running for president in order to extend the family's political dynasty. Trump said that he would need to think hard about how a presidential run would impact his other family members, particularly his two kids. Ultimately, Eric Trump said that his answer is yes and he believes that he could do it - and that other members of his family could do it too. "The real question is: 'Do you want to drag other members of your family into it?'" Trump told the outlet. "Would I want my kids to live the same experience over the last decade that I've lived? You know, if the answer was yes, I think the political path would be an easy one, meaning, I think I could do it." Trump added, 'And by the way, I think other members of our family could do it too.' Eric Trump is less of a political figure than some of his siblings though. While his older brother Donald Jr. has helped run President Trump's political operation for years and his older sister Ivanka is an official advisor to the president, Eric has spent significantly more time in the business side of things. He currently serves as co-executive vice-president of the Trump Organization alongside Donald Jr. But that isn't to say that Eric Trump has no political connections at all. He has made countless speeches and campaign trips in support of his father's presidency while his wife, Lara, is a former co-chair of the Republican National Committee. All three of President Trump's eldest children are currently eligible to run for president as the minimum required age is 35. Theoretically, any or all of them could make a push to fill their father's spot in the Oval Office as early as 2028. Will Eric Trump attempt to run for President?Eric Trump Was Asked If He Will Run For President first appeared on The Spun on Jun 29, 2025 This story was originally reported by The Spun on Jun 29, 2025, where it first appeared.
Yahoo
38 minutes ago
- Yahoo
Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.
I have owned Johnson & Johnson in the past. I like the company's business and its strong history of rewarding investors. There's one problem I just can't get past today. 10 stocks we like better than Johnson & Johnson › Johnson & Johnson (NYSE: JNJ) is an iconic U.S. healthcare giant. It has changed over the years, but today its focus is on pharmaceuticals and medical devices. And it is an industry leader in both spaces. There are a lot of positives with J&J, as it is more commonly known on Wall Street, but there's one dark cloud that I can't ignore. And the shadow from that cloud is why I just can't justify buying Johnson & Johnson today. When I look for stocks, I generally start with the dividend. And I don't look at the yield, instead focusing on the dividend growth streak. The longer a company has increased its dividend, the better, since only financially strong and well-run companies can hike the dividend year in and year out. J&J's streak is a huge 63 years, making it a Dividend King. I own a lot of Dividend Kings because I believe it is a clear indication that a business is well run. I also look at dividend yield. On that front, J&J's dividend yield is roughly 3.4% today. That's well above the S&P 500 index's 1.2% average yield and the average 1.7% in the healthcare sector. But, more to the point, it happens to be toward the high end of the historical yield range for Johnson & Johnson. That suggests this reliable dividend stock is not only offering an attractive yield, but it also looks attractively priced. On the valuation front, more traditional valuation metrics clearly back up the value proposition. J&J's price-to-sales, price-to-earnings, and price-to-book value ratios are all below their five-year averages. I haven't discussed the actual business, and Johnson & Johnson already looks like a strong buy. The business, meanwhile, just so happens to be one of the largest in the pharmaceutical and medical device spaces. J&J has the size and scale to invest heavily in research and development, regularly bringing out attractive new products. It has manufacturing, marketing, and distribution prowess that few can match. And it is generally a very well-respected supplier, so buyers are happy to work with Johnson & Johnson. And still I won't buy it and think that most others should avoid it, too. The problem with Johnson & Johnson is that I just can't overlook its talcum powder products. Or, more precisely, the class action lawsuits involving its talcum powder products. Past users claimed that J&J's talcum powder causes cancer. J&J denies this and is fighting the civil claims in court. The lawsuit numbers and liabilities are huge, well into the thousands of claimants and billions of dollars. To put some figures on it, there are over 60,000 lawsuits against J&J, and it recently tried to settle the issue with a $10 billion class action settlement offer. The details of the offer didn't pass muster with the judge overseeing the case, and it was denied. My real issue, however, isn't just the potential cost. It is how uncertain the outcome is in what amounts to a super high-profile problem. If the class action case goes to a jury trial, there's no telling what happens, and the case could linger for years as both sides continue to fight, as they almost certainly will. And, worse, J&J can't discuss the problem with shareholders because it is a sensitive legal issue. I don't blame management for not talking about the details of the lawsuits. The legal decisions J&J makes have to be kept private. But, at the same time, investors are mostly left in the dark as to what the company is going to do and why. I don't mind owning companies facing hardship, and I think J&J will survive the legal headwinds it faces. But from experience, I know I don't want to own companies that aren't able to discuss in reasonable detail what they are doing about the hardships they face. So, I can't, in good conscience, suggest anyone buy Johnson & Johnson because I wouldn't buy the stock myself right now. Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,731!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $945,846!* Now, it's worth noting Stock Advisor's total average return is 818% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It. was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Corn Bulls Get a Bounce into the Weekend
Corn futures closed the Friday session with gains of 6 to 8 cents in the front months as bears let off the gas into the weekend ahead of Monday's USDA reports. July was down 11 ¼ cents this week, with December losing 14 ¼ cents. The front month CmdtyView national average Cash Corn price was up 8 cents at $3.94. Ahead of the USDA Grain Stocks report, analysts estimate a total of 4.625 billion bushels of corn in stocks on June 1. That would be down 372 mbu from the year prior if realized. The range of estimates is at 4.459 to 4.798 bbu. Monday's Acreage report is expected to show 95.4 million acres for corn according to a Bloomberg survey, up ~200,000 acres from March. Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! The weekly CFTC Commitment of Traders report indicated large managed money spec traders in corn futures and options trimmed back 2,506 contracts from their large net short position. As of Tuesday, they held a net short of 182,282 contracts. Export Sales data has total commitments at 67.574 MMT, which is 99% of USDA's full year projection and slightly behind the 100% average sales pace. Statistics Canada data from this morning showed estimated Canadian corn acreage at 3.732 million acres, up 2.2% from a year ago. Jul 25 Corn closed at $4.17 1/2, up 8 cents, Nearby Cash was $3.94, up 8 cents, Sep 25 Corn closed at $4.11 1/2, up 7 1/2 cents, Dec 25 Corn closed at $4.27, up 6 cents, New Crop Cash was $3.84 3/8, up 6 1/4 cents, On the date of publication, Austin Schroeder did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
